<DOC>
	<DOCNO>NCT01263119</DOCNO>
	<brief_summary>The purpose study determine warfarin might affect LY2216684 give LY2216684 might affect warfarin body . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Study LY2216684 Warfarin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Are overtly healthy , determined medical history physical examination . Male subject Agree use reliable method birth control study 1 month follow last dose study drug . Female subject Are woman childbearing potential test negative pregnancy time enrollment , use reliable method birth control 6 week prior administration study drug , agree use reliable method birth control study 1 month follow last dose study drug ; Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause ( least 1 year without menses 6 month without menses follicle stimulate hormone [ FSH ] &gt; 40 mIU/mL ) . Have body weight &gt; 50 kg . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have venous access sufficient allow blood sample per protocol . Have normal blood pressure pulse rate ( sit position ) determine investigator . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly ethical review board ( ERB ) govern site . Are CYP2C9 extensive metabolizers determine genotyping assessment . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device study drug , concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy LY2216684 , warfarin , related compound . Are person previously complete withdrawn study study investigate LY2216684 within 6 month prior screen . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study . Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Have history show evidence significant active neuropsychiatric disease history suicide attempt ideation . Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis C and/or positive hepatitis C antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Are woman positive pregnancy test woman lactate . Intend use overthecounter prescription medication ( include hormonal contraceptive ) within 14 day prior dose unless deem acceptable investigator Sponsor 's medical monitor Use drug substance know substrate , inducer , inhibitor CYP2C19 CYP2C9 within 30 day prior dose . Have donate blood 500 mL within last month . Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption 48 hour prior dose period resident CRU ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , subject unwilling adhere study caffeine restriction . Have use tobaccocontaining nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior enrollment . Have consume grapefruit grapefruitcontaining product 7 day prior enrollment study . Have document suspected history glaucoma . History presence significant bleeding disorder , hematemesis , melanena , severe recurrent epistaxis , hemoptysis , clinically overt hematuria intracranial hemorrhage . Subjects history gastrointestinal ulcer hemorrhage . Personal family history coagulation bleed disorder reasonable suspicion vascular malformation , example , cerebral hemorrhage , aneurysm premature stroke ( cerebrovascular accident &lt; 65 year age ) . Selfreported history increase bleed trauma ( example , prolong bleed tooth extraction ) . History major surgery within 3 month screen . Planned surgery within 14 day last day dose . INR/PT , activate partial thromboplastin time ( APTT ) normal reference range screening . Positive fecal occult blood examination screen . Female subject history menorrhagia . Subjects determine unsuitable investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>